Genetic understanding of gynecological tumors could lead to new treatments

| October 13, 2016
Screen Shot at AM
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Researchers have unveiled the genetic landscape of carcinosarcomas (CSs), some of the most deadly tumors in ovarian and uterine cancers, and they say their findings may aid in the development of new treatments.

Study authors analyzed tumors from 68 women with ovarian and uterine CSs to identify the molecular basis of the tumor’s aggressive behavior, according to a news release. They sequenced all the genes from the participants’ tumors and identified genes that frequently mutated in CS, senior study author Dr. Alessandro Santin, an obstetrics, gynecology and reproductive sciences professor at Yale School of Medicine….

“In addition to mutations in cancer genes previously identified in uterine and ovarian carcinomas, we found an excess of mutations in genes encoding specific groups of proteins, which may potentially explain their mixed tissue characteristics,” Santin [said].

“…we demonstrated that the transition from carcinoma to sarcoma, which represent one of the main characteristics of these tumors, may happen at different times during the evolution of these cancers.”

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: Researchers identify underlying genetics of deadly gynecological tumors

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend